07.14.15
Headquarters: Leverkusen, Germany
twitter.com/Bayer
www.bayerpharma.com
TOP SELLING DRUGS
The big news during the year for the number one German pharma company was its purchase of Merck’s OTC business for $14.2 billion. Bayer recorded a 5% percent drop in revenue in 2014 with $14.6 billion, and maybe this deal will help swing sales in a positive direction. Included in the deal are the global trademark and prescription rights for Claritin and Afrin.
The companies also entered a clinical development collaboration to market and develop a portfolio of soluble guanylate cyclase (sGC) modulators, including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension (PAH) and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Adempas is currently marketed in the U.S., Europe and Japan. The companies will share costs and profits from the collaboration and implement a joint development and commercialization strategy.
The collaboration also includes development of vericiguat (BAY102), which is currently in Phase II trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer. In turn, Merck will make available its early-stage sGC compounds under similar terms.
Bayer also entered a global partnership with Orion Corp. for the development and commercialization of ODM-201, an investigational oral androgen receptor inhibitor entering Phase III development for the treatment of prostate cancer. The companies will jointly develop ODM-201, with Bayer covering the majority of development costs and responsibility for global commercialization.
twitter.com/Bayer
www.bayerpharma.com
Headcount: | 60,700 | |
Year Established: | 1971 | |
Revenues: | $51,341 | (+5%) |
Pharma Revenues: | $14,649 | (-5%) |
Net Income: | $2,982 | (-13%) |
R&D: | $2,283 | (+1%) |
TOP SELLING DRUGS
Drug | Indication | 2014 Sales | (+/-%) |
Xarelto | atrial fibrillation | $2,041 | 77% |
Kogenate | hemophilia | $1,348 | -8% |
Betaferon | multiple sclerosis | $995 | -21% |
Mirena | women’s health | $995 | 14% |
Nexavar | oncolgy | $940 | 0% |
Yaz | women’s health | $933 | -10% |
Eylea | macular degeneration | $923 | 128% |
The big news during the year for the number one German pharma company was its purchase of Merck’s OTC business for $14.2 billion. Bayer recorded a 5% percent drop in revenue in 2014 with $14.6 billion, and maybe this deal will help swing sales in a positive direction. Included in the deal are the global trademark and prescription rights for Claritin and Afrin.
The companies also entered a clinical development collaboration to market and develop a portfolio of soluble guanylate cyclase (sGC) modulators, including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension (PAH) and patients with chronic thromboembolic pulmonary hypertension (CTEPH). Adempas is currently marketed in the U.S., Europe and Japan. The companies will share costs and profits from the collaboration and implement a joint development and commercialization strategy.
The collaboration also includes development of vericiguat (BAY102), which is currently in Phase II trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer. In turn, Merck will make available its early-stage sGC compounds under similar terms.
Bayer also entered a global partnership with Orion Corp. for the development and commercialization of ODM-201, an investigational oral androgen receptor inhibitor entering Phase III development for the treatment of prostate cancer. The companies will jointly develop ODM-201, with Bayer covering the majority of development costs and responsibility for global commercialization.
Bayer has had a strong start to 2015, announcing early on that it expects earnings to increase by more than 10% this year. Backed by five strong drug launches at the end of 2014 it’s probably feeling fairly confident in its stance. Even so, the company has had trouble making everyone happy with profits not hitting the expected mark. Given that, the newly launched drugs Xarelto, Eylea, Adempas, Stivarga and Xofigo are set to bank them a huge cash haul in 2015 with the hope that its sales will top €4 billion and recent NICE approval of the latter for use in prostate cancer will surely help these along. It’s been a tough journey with the UK regulators, and even though they’ve insisted on a financial cap of treatment costs it is still an important feather in their cap. With five more drugs entering Phase III trials, Bayer seems to be on target for a few good years ahead. —Adele Graham-King |